DISCOUNT ZERTIFIKAT - BIOGEN IDEC | Real-time Boerse Frankfurt Warrants 01:56:17 2024-06-14 pm EDT | ||
| 142.6 EUR | +0.27% |
|
| Current month | +2.21% | ||
| 1 month | +2.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 142.6 | +0.27% |
| 24-06-13 | 142.2 | +1.03% |
| 24-06-12 | 140.8 | -0.49% |
| 24-06-11 | 141.4 | +0.09% |
| 24-06-10 | 141.3 | +0.52% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 01:56 pm EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VD39R2 |
| ISIN | DE000VD39R22 |
| Date issued | 2024-04-18 |
| Maturity | 2025-03-21 (278 Days) |
| Parity | 1 : 1 |
| Emission price | 138.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 142.9 € |
|---|---|
| Lowest since issue | 136 € |
| Spread | 1.63 € |
| Spread % | 1.13% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
231.7
USD
Average target price
284.6
USD
Spread / Average Target
+22.85%
- Stock Market
- Certificates
- Certificat
